Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

HLA-A, HLA-B, HLA-DRB1 Polymorphisms and Risk of Cervical Squamous Epithelial Cell Carcinoma: A Population Study in China

  • Xiao, Xue (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Liu, Li (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Li, Wei-Jie (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Liu, Juan (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Chen, Dun-Jin (Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University)
  • Published : 2013.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cervical cancer is the second most common cancer in women. HLA class I and II alleles polymorphisms have been shown to be associated with cervical cancer risk, but results have varied among different populations. In this study, the HLA-A, -B, and -DRB1 alleles among 100 southern Chinese women with cervical squamous cell carcinoma (SCC) were compared to 254 controls. Our results showed that $B^*51$:01:02 allele frequency was significantly higher in patients with SCC than in healthy controls ($P=3.17{\times}10^{-5}$, $P_c$=0.005, OR=26.7). Statistical analysis also revealed a significantly decreased frequency of $B^*51$:01:02 ($P=7.01{\times}10^{-4}$, $P_c$=0.03, OR=0.12) in patients with SCC when compared with healthy controls. These results indicate that HLA-$B^*51$:01:02 may confer susceptibility to SCC and HLA-$B^*51$:01:02 may contribute to resistance to the development of SCC in Chinese women. None of the HLA-A-B or HLA-A-B-DRB1 haplotypes were significantly different in cases and controls after multiple testing corrections, indicating the individual allele associations to be independent of the identified haplotypes. These results support the hypothesis that some HLA-B alleles could be involved with susceptibility for developing SCC.

Keywords

References

  1. Apple RJ, Erlich HA, Klitz W, et al (1994). HLA DR-DQ associations with cervical carcinoma show papillomavirustype specificity. Nat Genet, 6, 157-62. https://doi.org/10.1038/ng0294-157
  2. Armstrong EP (2010). Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm, 16, 217-30.
  3. Benjamini Y, Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological), 57, 289-300.
  4. Beskow AH, Josefsson AM, Gyllensten UB (2001). HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer, 93, 817-22. https://doi.org/10.1002/ijc.1412
  5. Bontkes HJ, van Duin M, de Gruijl TD, et al (1998). HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer, 78, 166-71. https://doi.org/10.1002/(SICI)1097-0215(19981005)78:2<166::AID-IJC8>3.0.CO;2-X
  6. Breitburd F, Ramoz N, Salmon J, Orth G (1996). HLA control in the progression of human papillomavirus infections. Semin Cancer Biol, 7, 359-71. https://doi.org/10.1006/scbi.1996.0045
  7. Carreon JD, Martin MP, Hildesheim A, et al (2005). Human leukocyte antigen class I and II haplotypes and risk of cervical cancer. Tissue Antigens, 66, 321-4. https://doi.org/10.1111/j.1399-0039.2005.00478.x
  8. Castro FA, Haimila K, Pasanen K, et al (2007). Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland. Int J STD AIDS, 18, 672-9. https://doi.org/10.1258/095646207782193803
  9. Chan DP, Cheung TH, Tam AO, et al (2005). Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. J Infect Dis, 192, 1749-56. https://doi.org/10.1086/497342
  10. Chan PK, Cheung JL, Cheung TH, et al (2007). HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. Gynecol Oncol, 105, 736-41. https://doi.org/10.1016/j.ygyno.2007.02.013
  11. Chan PK, Cheung JL, Cheung TH, et al (2006). HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women. Int J Cancer, 118, 1430-5. https://doi.org/10.1002/ijc.21528
  12. Cuzick J, Terry G, Ho L, et al (2000). Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer, 82, 1348-52. https://doi.org/10.1054/bjoc.1999.1103
  13. Excoffier L, Lischer HE (2010). Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour, 10, 564-7. https://doi.org/10.1111/j.1755-0998.2010.02847.x
  14. Forouzanfar MH, Foreman KJ, Delossantos AM, et al (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet, 378, 1461-84. https://doi.org/10.1016/S0140-6736(11)61351-2
  15. Hildesheim A, Schiffman M, Scott DR, et al (1998). Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev, 7, 1035-41.
  16. Howlader N, Noone A, Krapcho M, et al (2013). SEER Cancer Statistics Review, 1975-2010. National Cancer Institute.
  17. Maciag PC, Schlecht NF, Souza PS, et al (2000). Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev, 9, 1183-91.
  18. Odunsi K, Terry G, Ho L, et al (1996). Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer, 67, 595-602. https://doi.org/10.1002/(SICI)1097-0215(19960904)67:5<595::AID-IJC1>3.0.CO;2-P
  19. Sastre-Garau X, Loste MN, Vincent-Salomon A, et al (1996). Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer, 69, 159-64. https://doi.org/10.1002/(SICI)1097-0215(19960621)69:3<159::AID-IJC1>3.0.CO;2-Z
  20. Wu Y, Chen Y, Li L, et al (2006). Polymorphic amino acids at codons 9 and 37 of HLA-DQB1 alleles may confer susceptibility to cervical cancer among Chinese women. Int J Cancer, 118, 3006-11. https://doi.org/10.1002/ijc.21746
  21. Wu Y, Liu B, Lin W, et al (2007). Human leukocyte antigen class II alleles and risk of cervical cancer in China. Hum Immunol, 68, 192-200. https://doi.org/10.1016/j.humimm.2006.07.005
  22. Zehbe I, Hohn H, Pilch H, et al (2005). Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance. Int J Cancer, 117, 807-15. https://doi.org/10.1002/ijc.21226
  23. Zehbe I, Mytilineos J, Wikstrom I, et al (2003). Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol, 64, 538-42. https://doi.org/10.1016/S0198-8859(03)00033-8
  24. Zhao M, Qiu L, Tao N, et al (2013). HLA DRB allele polymorphisms and risk of cervical cancer associated with human papillomavirus infection: a population study in China. Eur J Gynaecol Oncol, 34, 54-9.

Cited by

  1. Changes in Median Ages at Death from Selected Cancer Types in Relation to HLA-DRB1/DQB1 vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4125
  2. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance vol.6, pp.2, 2017, https://doi.org/10.1080/2162402X.2016.1171447
  3. Study on the association of the polymorphism of HLA-II gene with leukemia vol.14, pp.1, 2017, https://doi.org/10.3892/ol.2017.6136
  4. Frequency distribution of HLA alleles and haplotypes in Uyghur women with advanced squamous cell cervical cancer and relation to HPV status and clinical outcome vol.297, pp.3, 2018, https://doi.org/10.1007/s00404-018-4662-3